- LGND Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
10-Q/A Filing
Ligand Pharmaceuticals (LGND) 10-Q/A2017 Q4 Quarterly report (amended)
Filed: 2 Nov 17, 12:00am
/s/ Matthew Korenberg |
Matthew Korenberg Vice President, Finance and Chief Financial Officer Duly Authorized Officer and Principal Financial Officer |
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.